Page last updated: 2024-11-04

pyruvic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyruvic acid, also known as 2-oxopropanoic acid, is a key intermediate in several metabolic pathways. It is produced during glycolysis, the breakdown of glucose, and is a precursor for many important biomolecules. Pyruvic acid can be converted to acetyl-CoA, which enters the citric acid cycle for energy production. It can also be converted to lactic acid during anaerobic respiration. Pyruvic acid is involved in gluconeogenesis, the synthesis of glucose from non-carbohydrate sources. It is also a precursor for amino acids, such as alanine. Pyruvic acid plays a crucial role in energy metabolism, and its levels are tightly regulated in the body. Studies on pyruvic acid are important to understand its role in various metabolic processes, including energy production, glucose homeostasis, and amino acid synthesis. Alterations in pyruvic acid levels can be indicative of metabolic disorders, such as diabetes. Research on pyruvic acid also focuses on its potential therapeutic applications, such as in cancer treatment and wound healing.'

Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1060
CHEMBL ID1162144
CHEBI ID32816
MeSH IDM0028719

Synonyms (97)

Synonym
acide pyruvique
2-oxopropionsaeure
alpha-oxopropionsaeure
2-ketopropionic acid
ch3cocooh
2-oxopropansaeure
CHEBI:32816 ,
NCIOPEN2_000039
NCHEMBIO867-COMP8
fema no. 2970
brn 0506211
nsc 179
einecs 204-824-3
propanoic acid, 2-oxo- (9ci)
ai3-11220
pyruvic acid (8ci)
pyruvic acid (natural)
inchi=1/c3h4o3/c1-2(4)3(5)6/h1h3,(h,5,6
127-17-3
2-oxopropionic acid
2-oxo-propionic acid
nsc-179
acetylformic acid
pyroracemic acid
alpha-ketopropionic acid
pyruvic acid
nsc179
propanoic acid, 2-oxo-
2-oxopropanoic acid
C00022
.alpha.-ketopropionic acid
pyruvic acid, 95%
pyruvic acid, natural, >=80%
pyruvic acid, >=97%, fg
DB00119
NCGC00165990-01
a-ketopropionic acid
alpha-keto propionic acid
LMFA01060077
pyruvic acid, 98%
acid, pyruvic
bdbm19473
P-9250 ,
B3CFF0AD-2F35-484C-B062-4AC88A1B2830
AKOS000118803
brenztraubensaeure
BMSE000112
P0579
CHEMBL1162144
NCGC00165990-02
4-03-00-01505 (beilstein handbook reference)
8558g7rutr ,
unii-8558g7rutr
dtxsid2021650 ,
tox21_303284
NCGC00257000-01
dtxcid801650
cas-127-17-3
tox21_202096
NCGC00259645-01
FT-0612738
propanoic acid, oxo-
pyruvic acid [fhfi]
pyruvic acid [who-dd]
pyruvic acid [inci]
pyruvic acid [mi]
4B5S
S3143
13c labeled pyruvic acid
gtpl4809
BBL027390
2-oxo propanoic acid
pyruvicacid
2-ketopropanoic acid
mfcd00002585
F2191-0254
pyruvic acid, technical, >=95.0% (t)
pyruvic acid, united states pharmacopeia (usp) reference standard
pyruvic acid, p.a., 98%
alpha-ketopropionate
a-ketopropionate
acetylformate
pyroracemate
2-oxopropionate
HY-Y0781
CS-W020190
Z104495240
Q213580
EN300-21306
AMY6082
2-oxopropanoic'acid
2-oxopropanoic acid, pyroracemic acid
2-oxopropanoicacid
brenztraubensaure
alpha-oxopropionsaure
2-oxopropionsaure
2-oxopropansaure

Research Excerpts

Overview

Pyruvic acid (PA) is an energy source for ATP synthesis in the tricarboxylic acid cycle that also acts as a reactive oxygen species (ROS) scavenger. It is an alpha-keto acid that presents keratolytic, antimicrobial and sebostatic properties.

ExcerptReferenceRelevance
"Pyruvic acid (PA) is an energy source for ATP synthesis in the tricarboxylic acid cycle that also acts as a reactive oxygen species (ROS) scavenger."( Pyruvic acid/ethyl pyruvate inhibits melanogenesis in B16F10 melanoma cells through PI3K/AKT, GSK3β, and ROS-ERK signaling pathways.
Sakamoto, K; Zhou, S, 2019
)
2.68
"Pyruvic acid is an important chemical in the carboxylate platform. "( Electrolyzing lactic acid in situ in fermentation broth to produce pyruvic acid in electrolysis cell.
Qian, P; Wang, B; Xixi, Z, 2019
)
2.19
"Pyruvic acid is a neuronal metabolic energy fuel that can also rapidly undergo decarboxylation to diffuse H(2)0(2) into H(2)0."( Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro.
Mazzio, E; Soliman, KF, 2003
)
2.48
"Pyruvic acid is an alpha-keto acid that presents keratolytic, antimicrobial, and sebostatic properties as well as the ability to stimulate new collagen production and elastic fibers formation. "( Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel.
Berardesca, E; Cameli, N; Carrera, M; Primavera, G, 2006
)
2
"Pyruvic acid is an effective scavenger of reactive oxygen species. "( Is pyruvate an endogenous anti-inflammatory molecule?
Das, UN, 2006
)
1.78
"Pyruvic acid is an important aqueous-phase intermediate."( Evidence for oligomer formation in clouds: reactions of isoprene oxidation products.
Altieri, KE; Carlton, AG; Lim, HJ; Seitzinger, SP; Turpin, BJ, 2006
)
1.06
"Pyruvic acid (PA) is an alpha-hydroxy acid with potent keratolytic properties. "( Treatment of warts with topical pyruvic acid: with and without added 5-fluorouracil.
Halasz, CL, 1998
)
2.03
"Pyruvic acid is an important organic acid widely used in the chemical and drug, as well as agrochemical, industries. "( Biotechnological production of pyruvic acid.
Chen, J; Li, Y; Lun, SY, 2001
)
2.04

Effects

Pyruvic acid (PA) has been demonstrated to be an important cancer biomarker. PA has a critical role in energy metabolism and a capability to nonenzymatically decarboxylate H 2O2 into H2O.

ExcerptReferenceRelevance
"Pyruvic acid has a critical role in energy metabolism and a capability to nonenzymatically decarboxylate H2O2 into H2O."( Cytoprotection of pyruvic acid and reduced beta-nicotinamide adenine dinucleotide against hydrogen peroxide toxicity in neuroblastoma cells.
Mazzio, EA; Soliman, KF, 2003
)
1.37
"Pyruvic acid (PA) has been demonstrated to be an important cancer biomarker. "( An enzyme-free sensing platform based on molecularly imprinted polymer/MWCNT composite for sub-micromolar-level determination of pyruvic acid as a cancer biomarker.
Alizadeh, T; Nayeri, S, 2020
)
2.21
"Pyruvic acid has a critical role in energy metabolism and a capability to nonenzymatically decarboxylate H2O2 into H2O."( Cytoprotection of pyruvic acid and reduced beta-nicotinamide adenine dinucleotide against hydrogen peroxide toxicity in neuroblastoma cells.
Mazzio, EA; Soliman, KF, 2003
)
1.37

Actions

ExcerptReferenceRelevance
"Pyruvic acid did not activate the leukocyte ALDH."( Mechanisms for plasma-mediated activation of human blood cell aldehyde dehydrogenase.
Gogoll, A; Helander, A, 1992
)
1

Toxicity

ExcerptReferenceRelevance
"5 LD50 and 1 LD50 doses in female rabbits resulted in significant changes in physiological, clinico-chemical and histological parameters."( Acute toxicity of methyl isocyanate, administered subcutaneously in rabbits: changes in physiological, clinico-chemical and histological parameters.
Jeevarathinam, K; Mukhopadhyay, S; Ray, US; Selvamurthy, W; Thakur, L, 1988
)
0.27
" There was even a toxic response form the mixture at concentrations where the chemicals alone yielded no such response."( Assessment of the toxicity of chemical mixtures with isolated rat hepatocytes: cadmium and chloroform.
Stacey, NH, 1987
)
0.27
" S-(1,2-Dichlorovinyl)-L-glutathione is not toxic when the cells are pretreated with AT-125, an inhibitor of gamma-glutamyl transpeptidase."( The role of glutathione conjugate metabolism and cysteine conjugate beta-lyase in the mechanism of S-cysteine conjugate toxicity in LLC-PK1 cells.
Hayden, P; Stevens, J; Taylor, G, 1986
)
0.27
" These results suggest that the acute toxic effects of commercially available PD on the integrity, proliferation and IL-1 ra production of MC can be avoided by the use of sodium pyruvate instead of sodium lactate."( Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells.
Brunkhorst, R; Mahiout, A, 1995
)
0.29
"86% glucose containing solutions, all negative effects became even more pronounced in the lactate group whereas after pre-exposure to pyruvate containing solution the toxic effects were absent."( Pyruvate anions neutralize peritoneal dialysate cytotoxicity.
Brunkhorst, R; Mahiout, A, 1995
)
0.29
"Subcutaneous administration of the LD50 dose of methyl isocyanate (MIC) to rats induced severe hyperglycaemia, lactic acidosis and uraemia in rats."( Influence of methylamine and N,N'-dimethylurea, the hydrolysis products of methyl isocyanate, on its systemic toxicity.
Jeevaratnam, K; Sugendran, K; Vaidyanathan, CS,
)
0.13
") increased LD50 values of CN(8."( Antidotal effect of dihydroxyacetone against cyanide toxicity in vivo.
Niknahad, H; O'Brien, PJ, 1996
)
0.29
" As a consequence, DNA SSBs promoted by tB-OOH do not appear to be toxic for the cell."( Pyruvate enhances DNA single-strand break formation while abolishing cytotoxicity in U937 cells exposed to tert-butylhydroperoxide.
Brambilla, L; Cantoni, O; Cattabeni, F; Guidarelli, A, 1996
)
0.29
" Of all tested reagents, organic mercury compounds arose as the most toxic reagents."( Hepatotoxic effects of SH-reagents in human and rat hepatocyte cultures and in situ perfused rat livers.
Boot, JH, 1996
)
0.29
" The method is rapid, precise, and lacks any toxic byproduct."( In vitro correlation between two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium laurylsulfate cytotoxicity.
Coiffard, C; Coiffard, LJ; De Roeck-Holtzhauer, Y; Rivalland, P; Verhulst, C, 1998
)
0.54
" Previous work has shown that 3,4-dichloroaniline is acutely toxic to the kidney and bladder."( 3,4-Dichlorophenylhydroxylamine cytotoxicity in renal cortical slices from Fischer 344 rats.
Ball, JG; Rankin, GO; Stoll, S; Valentovic, M, 2001
)
0.31
" The lactate/pyruvate ratio and the calcium content in tissues constitute direct evidences for the snails adaptation to toxic stress."( Copper sulphate (CuSO4) toxicity on tissue phosphatases activity and carbohydrates turnover in Achatina fulica.
Indra, D; Ramalingam, K, 2002
)
0.31
" Previous workers showed that the reactive-sulphur-containing fragment released from S -(1,1,2,2-tetrafluoroethyl)-L-cysteine and S -(1,2-dichlorovinyl)-L-cysteine is toxic by acting as a thioacylating agent - particularly of lysine residues in nearby proteins."( L-alanine-glyoxylate aminotransferase II of rat kidney and liver mitochondria possesses cysteine S-conjugate beta-lyase activity: a contributing factor to the nephrotoxicity/hepatotoxicity of halogenated alkenes?
Cooper, AJ; Jeitner, TM; Krasnikov, BF; Okuno, E, 2003
)
0.32
" The first group (A) consisted of patients with presumed NRTI-related adverse events (n=21), the second group (B) consisted of patients without adverse events (n=28), the third group (C) were HIV-infected patients without antiretroviral therapy (n=6) and the last group (D) were healthy controls (n=12)."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
" All patients with lactate values above 2700 micromol/l (eight) experienced adverse events."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
"Lactate levels were higher in patients with presumed NRTI-related adverse events."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
" Melatonin, being a potent free radical scavenger may reduce arsenic-induced free radical production, and thereby, eliminating its toxic effects."( Prospective protective role of melatonin against arsenic-induced metabolic toxicity in Wistar rats.
Chatterjee, AK; Pal, S, 2005
)
0.33
" We investigated the toxic effects of excess extracellular copper on motor neuronal cells expressing human mutant SOD1 (G93A), and evaluated the neuroprotective effects of energy metabolism intermediates or cofactors."( Pyruvate protects motor neurons expressing mutant superoxide dismutase 1 against copper toxicity.
Kim, HJ; Kim, JM; Kim, M; Lee, KW; Park, JH; Sung, JJ, 2005
)
0.33
" These findings indicate that SNP (presumably through increases in NO profile): (i) fails to improve bovine embryo development in vitro, (ii) exerts toxic effects, likely through ATP starvation induced by cytochrome c oxidase (oxidative phosphorylation) and glyceraldehyde-3-phosphate dehydrogenase (glycolysis) inhibition, and (iii) may affect albumin endocytosis/hydrolysis or protein biosynthesis, rather than causing a loss of intracellular amino acids or simply depressing their metabolism."( Embryotoxicity of the nitric oxide donor sodium nitroprusside in preimplantation bovine embryos in vitro.
Orsi, NM, 2006
)
0.33
" A toxic dose of acetaminophen (800 mg/kg body weight intraperitoneally) induced severe abnormality in all basic parameters with apparent toxicity in liver (enlargement of hepatocytes, loss of cytoplasmic content with disruption in the hepatic plates and sinusoidal dilation) and renal tissue (glomerular damage with congestion of tubules)."( Effect of crude sulphated polysaccharide from brown algae against acetaminophen-induced toxicity in rats.
Raghavendran, HR; Srinivasan, P, 2008
)
0.35
" Two recombinant Escherichia coli strains capable of expressing N-acetyl-D-glucosamine 2-epimerase and N-acetyl-D-neuraminic acid aldolase were constructed based on a highly efficient temperature-responsive expression system which is safe compared to chemical-induced systems and coupled in Neu5Ac production."( An efficient method for N-acetyl-D-neuraminic acid production using coupled bacterial cells with a safe temperature-induced system.
Du, M; Gu, L; He, X; Ma, C; Qiu, J; Tao, F; Xu, P; Zhang, Y, 2010
)
0.36
" BMS-488043 was generally safe and well tolerated."( Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Colonno, R; Grasela, DM; Hanna, GJ; Hellinger, JA; Krystal, M; Lalezari, J; Lin, P; Nettles, R; Persson, A; Wohl, DA, 2011
)
0.37
" We propose a model of toxic action based on monoHAA-mediated inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a target cytosolic enzyme."( Pyruvate remediation of cell stress and genotoxicity induced by haloacetic acid drinking water disinfection by-products.
Dad, A; Jeong, CH; Pals, JA; Plewa, MJ; Wagner, ED, 2013
)
0.39
"Cadmium is a toxic metal with no biological function in higher-order mammals."( In vitro protection by pyruvate against cadmium-induced cytotoxicity in hippocampal HT-22 cells.
Liu, R; Poteet, E; Ryou, MG; Winters, A; Xie, L; Yang, SH, 2014
)
0.4
" Acetaminophen (APAP) is a commonly used and effective analgesic/antipyretic agent and relatively safe drug even in long-term treatment."( [Investigation of Predisposition Biomarkers to Identify Risk Factors for Drug-induced Liver Injury in Humans: Analyses of Endogenous Metabolites in an Animal Model Mimicking Human Responders to APAP-induced Hepatotoxicity].
Kobayashi, A; Kondo, K; Sugai, S, 2015
)
0.42
" In agreement with in vivo studies, acetaminophen (APAP) toxicity was most profound in HUVEC mono-cultures; whilst in C3A:HUVEC co-culture, cells were less susceptible to the toxic effects of APAP, including parameters of oxidative stress and ATP depletion, altered redox homeostasis, and impaired respiration."( Acetaminophen cytotoxicity is ameliorated in a human liver organotypic co-culture model.
Hayes, PC; Morley, SD; Navarro, M; Nelson, LJ; Plevris, JN; Samuel, K; Treskes, P; Tura-Ceide, O, 2015
)
0.42
"The liver toxicity of valproic acid (VPA) is an established side effect of this widely used antiepileptic drug, which is extremely problematic for patients with metabolic epilepsy and particularly epilepsy due to mitochondrial dysfunction."( Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase.
Bialer, M; Eisenkraft, A; Elger, CE; Kudin, AP; Kunz, WS; Mawasi, H, 2017
)
0.46
"With increasing human exposure to vanadium-containing compounds and growing concern over their impact on human health, identification of safe methods for efficient treatment of vanadium poisoning may be of value."( Protective activity of pyruvate against vanadium-dependent cytotoxicity in Chinese hamster ovary (CHO-K1) cells.
Gołębiowska, D; Zwolak, I, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ."( The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits.
Ho, Y; Hsu, KY; Song, DJ, 1995
)
0.63
"Optimizing pharmacokinetic properties to improve oral exposure is a common theme in modern drug discovery."( Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Colonno, RJ; D'Arienzo, CJ; Gesenberg, C; Hansel, SB; Kadow, JF; Lin, PF; Malinowski, J; Marino, AM; Meanwell, NA; Wang, T; Yang, Z; Zadjura, LM, 2010
)
0.36
"The major obstacle for the development of targeted therapies is the lack of pharmacodynamic (PD) biomarkers to provide an early readout of biological activities."( Metabolomics combined with pattern recognition and bioinformatics analysis methods for the development of pharmacodynamic biomarkers on liver fibrosis.
Fang, J; Qiu, M; Wang, L; Wang, Y; Zhang, Y, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"We studied the prooxidant and cytotoxic action of thiols N-acetylcystein (NAC) and glutathione (GSH) combined with vitamin Bl2b."( [Prooxidant and cytotoxic action of N-acetylcysteine and glutathione combined with vitamin Bl2b].
Akatov, VS; Faskhutdinova, AA; Kudriavtsev, AA; Solov'ev, VV; Solov'eva, ME, 2007
)
0.34
" The results of additional experiments presented here indicate that the RNase G mutation, in combination with cra mutation, caused the increased production of pyruvic acid from glucose, which was then preferentially converted to valine due to the ilvIH mutation, resulting in depletion of isoleucine."( Increased production of pyruvic acid by Escherichia coli RNase G mutants in combination with cra mutations.
Nagai, K; Nakamura, N; Sakai, T; Umitsuki, G; Wachi, M, 2007
)
0.84
" When acetoacetate, beta-hydroxybutyrate, or KIC were combined with MMS, or either ketone body was combined with lactate, insulin release was stimulated 10-fold to 20-fold the controls (almost as much as with glucose)."( Acetoacetate and beta-hydroxybutyrate in combination with other metabolites release insulin from INS-1 cells and provide clues about pathways in insulin secretion.
Brown, LJ; Hasan, NM; Kendrick, MA; Longacre, MJ; MacDonald, MJ; Stoker, SW, 2008
)
0.35
" Reduced IC combined with intracranial volume insults leads to metabolic disturbances in a rat model."( Metabolic effects of a late hypotensive insult combined with reduced intracranial compliance following traumatic brain injury in the rat.
Contant, CF; Enblad, P; Goiny, M; Nilsson, P; Piper, I; Salci, K, 2010
)
0.36
" YILWΔalaTpXMJ19thrABC exhibited a cumulative reduction of these by-products excretion, which indicated that thrABC overexpression combined with alaT deletion resulted in the metabolic flux redistribution from 2-ketobutyrate and pyruvate to L-isoleucine synthesis, and decreased the fluxes to by-products synthesis accordingly."( Enhancing (L)-isoleucine production by thrABC overexpression combined with alaT deletion in Corynebacterium glutamicum.
Chen, N; Wang, J; Wen, B; Xie, X; Xu, Q; Zhang, C, 2013
)
0.39
" The effect of LLL was further bolstered by combination with metabolic substrates such as pyruvate or lactate both in vivo and in vitro."( Low-level light in combination with metabolic modulators for effective therapy of injured brain.
Dong, T; Hamblin, MR; Wu, MX; Zhang, Q, 2015
)
0.42
"Sustained, low- and mid-level (3-6%), radial stretching combined with varying concentrations of sodium pyruvate (NaPy) supplement increase the migration rate during microscale gap closure following an in vitro injury; NaPy is a physiological supplement often used in cell-culture media."( Non-damaging stretching combined with sodium pyruvate supplement accelerate migration of fibroblasts and myoblasts during gap closure.
Alvarez-Elizondo, MB; Berkovitch, Y; Marom, A; Toume, S; Weihs, D, 2019
)
0.51
"In myoblasts, the smallest evaluated strain (3%, minimal risk of damage) combined with preinjury (1 mM) and post-injury exogenous NaPy supplements accelerated gap closure in a statistically significant manner; response was NaPy concentration dependent."( Non-damaging stretching combined with sodium pyruvate supplement accelerate migration of fibroblasts and myoblasts during gap closure.
Alvarez-Elizondo, MB; Berkovitch, Y; Marom, A; Toume, S; Weihs, D, 2019
)
0.51
" In summary, the results demonstrate that pyruvate metabolism acts as novel targetable metabolic vulnerabilities for HCC treatment in combination with a glutamine-deficient diet."( Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Bao, MH; Chan, CY; Chen, Y; Lee, D; Tse, AP; Wei, L; Wong, BP; Wong, CC; Yang, C; Yuen, VW; Zhang, MS, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
"BMS-488043 is an HIV-attachment inhibitor that exhibited suboptimal oral bioavailability upon using conventional dosage forms prepared utilizing micronized crystalline drug substance."( Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Brown, J; Desikan, S; Fakes, MG; Franchini, MK; Gandhi, RB; Hsieh, A; Lai, C; Qian, F; Toale, H; Vakkalagadda, BJ, 2009
)
0.35
" The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively."( Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Colonno, RJ; D'Arienzo, CJ; Gesenberg, C; Hansel, SB; Kadow, JF; Lin, PF; Malinowski, J; Marino, AM; Meanwell, NA; Wang, T; Yang, Z; Zadjura, LM, 2010
)
0.36
" BMS-488043 is an orally bioavailable AI that binds to gp120 of HIV-1 and abrogates its binding to CD4(+) lymphocytes."( In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Alexander, L; Colonno, R; Eggers, B; Fan, L; Fang, H; Fang, J; Gong, YF; Grasela, D; Hanna, GJ; Kadow, J; Krystal, M; Langley, DR; Lin, PF; Nowicka-Sans, B; Wang, T; Zhang, S; Zhou, N, 2011
)
0.37
" We hypothesized that the ameliorating effect of HBO2 is caused by an increased bioavailability of NO, which can be attenuated by injection of the selective neuronal NO synthase inhibitor, 7-nitroindazole, preceding the HBO2 procedure."( Neuronal nitric oxide inhibition attenuates the protective effect of HBO2 during cyanide poisoning.
Hedetoft, M; Hyldegaard, O; Olsen, NV; Polzik, P,
)
0.13
" CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that has activity in Triple receptor-Negative Breast Cancer (TNBC) cell lines and evidence of efficacy in advanced TNBC patients."( Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Baguley, BC; Dechaume, AL; Katt, WP; Leung, EY; Murray, PM; Singleton, DC, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Insulin dose-response curves revealed similar sensitivities and responsiveness."( Effect of insulin on glucose utilization in epitrochlearis muscle of rats with streptozocin-induced NIDDM.
Gavin, JR; Karl, IE; Levy, J, 1990
)
0.28
" The inclusion of a dosed physical training in the therapy and rehabilitation programme, respectively, of patients with chronic liver diseases can be recommended, particularly, since there is no causal medicamentous therapy of chronic liver diseases possible at present."( [Effect of physical training on the aerobic-anaerobic transition in chronic liver diseases].
Buhl, H; Krause, P; Rogos, R, 1988
)
0.27
" Alterations in L/P ratio preceded the release of cytosolic ALT and at 4 h a well defined dose-response relationship existed between the benoxaprofen concentration and the observed increases in the L/P ratio and ALT release."( Benoxaprofen induced toxicity in isolated rat hepatocytes.
Cassidy, MR; Drew, R; Knights, KM, 1986
)
0.27
"The role of the increased hepatocellular redox-state [( NADH]/[NAD+] ratio) as a mechanism underlying hepatic triglyceride deposition after acute ethanol dosing has been investigated in the rat."( The role of the hepatocellular redox state in the hepatic triglyceride accumulation following acute ethanol administration.
Chakraborty, J; Ryle, PR; Thomson, AD, 1986
)
0.27
" Dose-response studies with MGBG (0 to 30 microM for 40 to 48 hr) revealed that, of the parameters related to polyamine metabolism (i."( Biochemical and ultrastructural characterization of human cell variants resistant to the antiproliferative effects of methylglyoxal bis(guanylhydrazone).
Kramer, DL; Porter, CW; Wiseman, A; Zychlinski, L, 1983
)
0.27
"This study was performed in part to establish an endotoxin dosage in miniature swine that would yield reproducible cardiovascular and metabolic aberrations over a specific 6-h sampling period, minimizing lethality during that time."( Endotoxin dose. I. Hemodynamic, metabolic, and lethal consequences in Yucatan minipigs.
Chandrasena, LG; Cleek, JL; Fettman, MJ; Hand, MS; Phillips, RW, 1983
)
0.27
" Chronic daily dosing caused lowering of these metabolites and a delay in the return of lactate to basal levels for 48 hr after the final dose."( Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate.
Evans, OB; Stacpoole, PW, 1982
)
0.26
" Dose-response curves for the effect of pentobarbital on respiratory activity of each cell type were constructed with the two substrates."( Differential effect of pentobarbital on chick neurons and astrocytes grown in culture.
Roth-Schechter, BF; Tholey, G, 1982
)
0.26
" Since it is very difficult to reproducibly achieve the right oxygen dosage in large-scale fermentations, non-Saccharomyces yeasts are therefore not suitable for large-scale alcoholic fermentation of sugar-containing waste streams."( Kinetics of growth and sugar consumption in yeasts.
Pronk, JT; van Dijken, JP; Weusthuis, RA, 1993
)
0.29
" This dosage can be used to study the barrier properties of the corneocyte layer without destroying the artificial skin."( In vitro correlation between two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium laurylsulfate cytotoxicity.
Coiffard, C; Coiffard, LJ; De Roeck-Holtzhauer, Y; Rivalland, P; Verhulst, C, 1998
)
0.54
" Treatment of cumulus-enclosed or denuded oocytes with increasing concentrations of cortisol or DEX for 48 h resulted in a dose-response inhibition of germinal vesicle breakdown (GVB)."( Effects of glucocorticoids on maturation of pig oocytes and their subsequent fertilizing capacity in vitro.
Chen, WY; Li, PS; Yang, JG, 1999
)
0.3
" In conclusion, this study suggests that short-term administration of LA at high dosage to normal and diabetic rats causes an inhibition of gluconeogenesis secondary to an interference with hepatic fatty acid oxidation."( Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats.
Bashan, N; Gutman, A; Khamaisi, M; Potashnik, R; Rudich, A; Tritschler, HJ, 1999
)
0.3
"The purposes of the present studies were to test the hypotheses that lower dosages of oral pyruvate ingestion would increase blood pyruvate concentration and that the ingestion of a commonly recommended dosage of pyruvate (7 g) for 7 days would enhance performance during intense aerobic exercise in well-trained individuals."( Pyruvate ingestion for 7 days does not improve aerobic performance in well-trained individuals.
Dyck, DJ; Morrison, MA; Spriet, LL, 2000
)
0.31
" In heart fibers a dosage of 100 microg LPS."( Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function.
Gellerich, FN; Neuhof, C; Opalka, JR; Trumbeckaite, S; Zierz, S, 2001
)
0.31
" Oxygen uptake by and energy charge in jejunal tissue were unaffected at 1 and 3 h after dosing by gavage with indomethacin."( Effects of indomethacin on energy metabolism in rat jejunal tissue in vivo.
Bjarnason, I; Jacob, M; Simpson, RJ, 2002
)
0.31
" A lower pyruvate concentration of 250 mg/kg was not protective; however, quadruple applications at this dosage was effective in reducing lesion volumes."( Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Kim, SU; McLarnon, JG; Ryu, JK, 2003
)
0.32
"2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12."( Chronic treatment of mitochondrial disease patients with dichloroacetate.
Barshop, BA; Haas, RH; Levine, F; Loupis-Geller, A; McGowan, KA; Naviaux, RK; Nyhan, WL,
)
0.13
" Reproducible shifts in the dose-response of skeletal muscle to caffeine and halothane are the basis of the current in vitro diagnostic caffeine-halothane contracture test."( Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina, S; Bünger, R; Cowan, G; Karaian, J; Mongan, P; Muldoon, S, 2006
)
0.33
" We performed 13C nuclear magnetic resonance spectroscopy on brain extracts from soman-poisoned mice (160 microg/kg; 1 LD50) that had been dosed with 13C-labeled glucose or pyruvate intravenously."( Cerebral metabolism of glucose and pyruvate in soman poisoning. A 13C nuclear magnetic resonance spectroscopic study.
Gonzalez, SV; Hassel, B; Nguyen, N; Rise, F, 2007
)
0.34
" In order to achieve optimal physical performance, further investigation as to dosage of magnesium supplementation is needed."( Effects of magnesium sulfate on dynamic changes of brain glucose and its metabolites during a short-term forced swimming in gerbils.
Chen, SH; Cheng, FC; Cheng, SM; Lee, CP; Lin, MT; Pan, HC; Yang, DY, 2007
)
0.34
"BMS-488043 is an HIV-attachment inhibitor that exhibited suboptimal oral bioavailability upon using conventional dosage forms prepared utilizing micronized crystalline drug substance."( Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Brown, J; Desikan, S; Fakes, MG; Franchini, MK; Gandhi, RB; Hsieh, A; Lai, C; Qian, F; Toale, H; Vakkalagadda, BJ, 2009
)
0.35
" In normal rats, Michaelis-Menten kinetics were able to describe the dose-response of the fitted exchange rate constants with a 13."( Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice.
Albers, MJ; Bok, R; Chen, AP; Hurd, RE; Kurhanewicz, J; Nelson, SJ; Park, I; Tropp, J; Vigneron, DB; Yen, YF; Zhang, V; Zierhut, ML, 2010
)
0.36
" Multivariate analysis showed that statin dosage was independently associated with MD (OR:1."( Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease.
Chan, HT; Dai, YL; Fong, B; Lau, CP; Lee, SW; Li, SW; Luk, TH; Siu, CW; Tam, S; Tse, HF; Yiu, KH, 2010
)
0.36
" These results offer an explanation for the steep dose-response curve of GHB seen in vivo, and suggest potential target receptors for further investigation."( γ-Hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB.
Balcar, VJ; Hanrahan, JR; Maher, AD; Nasrallah, FA; Rae, CD, 2010
)
0.36
" These effects were all reversed by co-treatment with pyruvate at a well-tolerated dosage (1000 mg/kg)."( Protective effect of pyruvate against ethanol-induced apoptotic neurodegeneration in the developing rat brain.
Kim, MO; Koh, PO; Lee, HY; Naseer, MI; Ullah, I; Ullah, N, 2011
)
0.37
" The data showed that prodrug 4 had excellent potential to significantly reduce dissolution rate-limited absorption following oral dosing in humans."( Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2
Bender, JA; Chen, CP; Chien, C; Colonno, RJ; Connolly, TP; Grasela, D; Kadow, JF; Lin, PF; Mathew, M; Meanwell, NA; Morgan, D; Parker, D; Ueda, Y; Wang, T; Yang, Z; Yeung, KS; Zheng, M; Zhu, J, 2012
)
0.38
" However, some patients encounter hepatotoxicity after repeated APAP dosing at therapeutic doses."( Enhancement of acetaminophen-induced chronic hepatotoxicity in restricted fed rats: a nonclinical approach to acetaminophen-induced chronic hepatotoxicity in susceptible patients.
Hashimoto, T; Kobayashi, A; Kondo, K; Kuno, H; Shoda, T; Sugai, S; Suzuki, Y; Takahashi, A; Toyoda, K; Yamada, N, 2012
)
0.38
" Dosing was based on haplotype variation in glutathione transferase zeta 1/maleylacetoacetate isomerase (GSTZ1/MAAI), which participates in DCA and tyrosine catabolism."( Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
Coats, BS; Dunbar, EM; Forder, JR; Langaee, T; Lew, A; Shroads, AL; Shuster, JJ; Stacpoole, PW; Wagner, DA, 2014
)
0.4
" The importance of genetic-based dosing is confirmed and should be incorporated into future trials of chronic DCA administration."( Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
Coats, BS; Dunbar, EM; Forder, JR; Langaee, T; Lew, A; Shroads, AL; Shuster, JJ; Stacpoole, PW; Wagner, DA, 2014
)
0.4
" Tigecycline is relatively unstable after reconstitution, and this instability may limit the use of the drug in ambulatory infusions for the treatment of infection and may prevent the development of optimal dosing schedules for the treatment of AML."( A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity.
Goard, CA; Gronda, M; Hurren, R; Jhas, B; Jitkova, Y; Schimmer, AD; Wang, X, 2014
)
0.4
" In order to enhance the production of human-like collagen (HLC) II, pyruvate was added into fermentation broth, and response surface methodology (RSM) to optimize the addition time and dosage of pyruvate and the concentration of phosphate buffer."( An approach for enhancing the production of human-like collagen II by enlarging the metabolic flux at pyruvate node.
Chenhui, Z; Daidi, F; Gaoping, Z; Xiaoxuan, M; Zifang, S, 2014
)
0.4
" Plasma and urinary glutathione-related metabolomes and liver function parameters were measured during the dosing period."( [Investigation of Predisposition Biomarkers to Identify Risk Factors for Drug-induced Liver Injury in Humans: Analyses of Endogenous Metabolites in an Animal Model Mimicking Human Responders to APAP-induced Hepatotoxicity].
Kobayashi, A; Kondo, K; Sugai, S, 2015
)
0.42
" Pyruvate treatment also lowered the dosage of vasoconstrictor phenylephrine required to maintain systemic arterial pressure at 15-60 min recovery, hastened clearance of excess glucose, elevated arterial bicarbonate, and raised arterial pH; these statistically significant effects persisted up to 3 h after sodium pyruvate infusion, while infusion-induced hypernatremia subsided."( Pyruvate stabilizes electrocardiographic and hemodynamic function in pigs recovering from cardiac arrest.
Cherry, BH; Hollrah, RA; Hoxha, B; Mallet, RT; Nguyen, AQ; Olivencia-Yurvati, AH; Williams, AG, 2015
)
0.42
" Other two groups were the intravenous (IV) resuscitation (group VR) with lactated Ringer's solution with the same dosage and no fluid rehydration (group NR)."( Pyruvate in oral rehydration salt improves hemodynamics, vasopermeability and survival after burns in dogs.
Bai, XD; Guo, SJ; Hu, S; Hu, XH; Li, ZY; Liu, R; Wang, SM; Zhou, FQ, 2016
)
0.43
" However, siRNA dosing data suggest that it may be possible to identify a dose that limits changes in liver organic acid levels, while maintaining a desired effect of reducing glyoxylate to oxalate synthesis."( Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.
Erbe, D; Fargue, S; Holmes, RP; Knight, J; Liebow, A; Wood, KD, 2019
)
0.51
" Such non-monotonic dose-response effects of iAs on glucose tolerance shed light on the complex interactions between iAs and the systemic glucose metabolism, which could potentially help reconcile some of the conflicting results in human epidemiological studies."( Non-monotonic dose-response effects of arsenic on glucose metabolism.
Ding, G; Gong, Y; Li, X; Liu, J; Qian, J; Qian, S; Sun, Z; Xue, Y; Zhou, W; Zhuang, Z, 2019
)
0.51
" After daily dosing of etavopivat over 5 consecutive days in NHPs, ATP was increased by 38% from baseline."( Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Drake, A; Fessler, R; Forsyth, S; Fulzele, K; Guichard, S; Kalfa, TA; Konstantinidis, DG; Marshall, CG; Ribadeneira, MD; Schroeder, P; Seu, KG; Wilker, E, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (187)

PathwayProteinsCompounds
Amino acid synthesis and interconversion (transamination)2343
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Phenylalanine and tyrosine catabolism1131
Alanine Metabolism513
Citric Acid Cycle2127
Urea Cycle1325
Glycine and Serine Metabolism2452
Glutamate Metabolism2244
Cysteine Metabolism923
Glycolysis1423
Pyruvate Metabolism2139
Gluconeogenesis2232
Glucose-Alanine Cycle810
Amino Sugar Metabolism1731
Ammonia Recycling1227
Pyruvaldehyde Degradation37
Primary Hyperoxaluria Type I513
Pyruvate Carboxylase Deficiency513
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Lactic Acidemia513
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Transfer of Acetyl Groups into Mitochondria919
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
Carbamoyl Phosphate Synthetase Deficiency1325
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
Non-Ketotic Hyperglycinemia2452
2-Hydroxyglutric Aciduria (D and L Form)2244
Tay-Sachs Disease1731
Hyperglycinemia, Non-Ketotic2452
beta-Mercaptolactate-Cysteine Disulfiduria923
Glycogenosis, Type VII. Tarui Disease1423
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Succinic Semialdehyde Dehydrogenase Deficiency2244
Fanconi-Bickel Syndrome1423
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
3-Phosphoglycerate Dehydrogenase Deficiency2452
Cystinosis, Ocular Nonnephropathic923
2,3-Dihydroxybenzoate Biosynthesis411
Biosynthesis of Siderophore Group Nonribosomal Peptides1821
D-Alanine Metabolism611
Lysine Biosynthesis1924
Glycolysis and Pyruvate Dehydrogenase2428
L-Alanine Metabolism1016
D-Glucarate and D-Galactarate Degradation1022
Serine Biosynthesis and Metabolism1020
Valine Biosynthesis912
Isoleucine Biosynthesis1622
Gluconeogenesis from L-Malic Acid2024
Galactitol and Galactonate Degradation1416
Fucose and Rhamnose Degradation1218
Hexuronide and Hexuronate Degradation1520
Folate Biosynthesis1126
Fructose Metabolism1520
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
Sulfur Metabolism2833
Sulfur Metabolism (Butanesulfonate)2834
Sulfur Metabolism (Propanesulfonate)2834
Sulfur Metabolism (Ethanesulfonate)2834
Sulfur Metabolism (Isethionate)2834
Sulfur Metabolism (Methanesulfonate)2834
Secondary Metabolites: Threonine Biosynthesis from Aspartate715
Secondary Metabolites: Valine and L-Leucine Biosynthesis from Pyruvate1024
Secondary Metabolites: Ubiquinol Biosynthesis922
2-Oxopent-4-enoate Metabolism1725
Menaquinol Biosythesis1224
Tryptophan Metabolism II623
Ketogluconate Metabolism1017
N-Acetylneuraminate, N-Acetylmannosamine, and N-Acetylglucosamine Degradation613
2-Oxopent-4-enoate Metabolism 21725
Secondary Metabolites: Ubiquinol Biosynthesis 2923
Thiazole Biosynthesis I314
Enterobactin Biosynthesis514
Hydrogen Sulfide Biosynthesis I511
L-Lactaldehyde Degradation (Aerobic)27
Methylglyoxal Degradation IV410
Pyruvate Decarboxylation to Acetyl-CoA37
Methylglyoxal Degradation II25
Pyruvate to Cytochrome bd Terminal Oxidase Electron Transfer48
D-Serine Degradation27
L-Cysteine Degradation18
Methylglyoxal Degradation I39
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
Glycolysis I1023
Glycine Metabolism1127
Serine Metabolism1025
Tetrahydrofolate Biosynthesis829
Ethanol Fermentation1527
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Selenocompound Metabolism923
Vitamin B6228
Glutamine Metabolism2225
Glutamic Acid Metabolism1317
C5-Branched Dibasic Acid Metabolism511
Butanoate Metabolism922
Monobactam Biosynthesis718
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
ATP + Pyruvic acid + CO2 + H2O = ADP + Oxaloacetic acid + Orthophosphate ( Alanine,Aspartic acid and Asparagine metabolism )17
L-Alanine + 2-Oxo-glutaric acid = Pyruvic acid + L-Glutamic acid ( Glycolysis and Gluconeogenesis )24
L-Alanine + Glyoxylic acid = Pyruvic acid + Glycine ( Glycolysis and Gluconeogenesis )24
Citrate cycle ( Citrate cycle )2129
ATP + Pyruvic acid + CO2 + H2O = ADP + Oxaloacetic acid + Orthophosphate ( Glycolysis and Gluconeogenesis )17
Glutamic acid and Glutamine metabolism ( Glutamic acid and Glutamine metabolism )1926
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
L-Serine + Pyruvic acid = Hydroxy-pyruvic acid + L-Alanine ( Glycine and Serine metabolism )14
NAD+ + (S)-Lactic acid = NADH + Pyruvic acid ( Pyruvate metabolism )44
NAD+ + (S)-Malic acid = NADH + Pyruvic acid + CO2 ( Pyruvate metabolism )15
NAD+ + (R)-Lactic acid = NADH + Pyruvic acid ( Pyruvate metabolism )14
Glycolysis and Gluconeogenesis ( Glycolysis and Gluconeogenesis )2718
Methionine and Cysteine metabolism ( Methionine and Cysteine metabolism )2342
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Pyruvate metabolism ( Pyruvate metabolism )3027
Pyruvic acid + Enzyme N6-(lipoyl)lysine = [dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine + CO2 ( Pyruvate metabolism )36
Aerobic glycolysis020
Amino acid metabolism pathway excerpt: histidine catabolism extension016
LPS and Citrate Signaling and Inflammation2311
Citrate Cycle1930
MEP/DOXP Pathway819
Ethylmalonic encephalopathy311
Dravet syndrome: Scn1a-A1783V point mutation model789
Metabolic pathways of fibroblasts1718
TCA cycle (plant)121
Metabolic Epileptic Disorders2589
fermentation06
glycine biosynthesis from alanine02
cysteine degradation06
TCA cycle, aerobic respiration020
alanine degradation02
tyrosol biosynthesis06
methylglyoxal pathway09
ubiquinone (coenzyme Q) biosynthesis026
serine degradation03
superpathway of glycine biosynthesis04
cysteine and homocysteine interconversion09
N-acetylglucosamine N-acetylmannosamine and N-acetylneuraminic acid dissimilation012
Central carbon metabolism019
TCA cycle010
Hexoses metabolism in proximal tubules016
Gluconeogenesis012
Principal pathways of carbon metabolism07
AtMetExpress overview0109
Alanine and aspartate metabolism015
Type II diabetes mellitus04
Trans-sulfuration pathway014
TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc)015
HIF1A and PPARG regulation of glycolysis07
TCA cycle nutrient use and invasiveness of ovarian cancer04
Metabolism overview078
Biochemical pathways: part I0466
NAD+ metabolism014
Amino acid metabolism094
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017
Acetylcholine synthesis05
Glucose homeostasis021

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
progesterone receptorHomo sapiens (human)Potency44.65870.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.86660.003041.611522,387.1992AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.87780.000229.305416,493.5996AID743075
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency17.96360.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.55570.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency19.58700.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki270.07651.10006.67899.1201AID360149
Prolyl 4-hydroxylaseParamecium bursaria Chlorella virus 1IC50 (µMol)1,000.00005.00006.26678.5000AID1543452
Solute carrier family 22 member 6Mus musculus (house mouse)Ki11,961.29980.40745.02179.4000AID360150
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki26,000.00000.02300.07000.1490AID681570
Alpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)IC50 (µMol)1,000.00003.00006.10009.8000AID734755
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Monocarboxylate transporter 1Rattus norvegicus (Norway rat)Km1,755.00002.28002.66503.0500AID679950; AID681605
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (148)

Processvia Protein(s)Taxonomy
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
lactate transmembrane transportMonocarboxylate transporter 2Homo sapiens (human)
transport across blood-brain barrierMonocarboxylate transporter 2Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 2Homo sapiens (human)
plasma membrane lactate transportMonocarboxylate transporter 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
positive regulation of retinoic acid receptor signaling pathwayC-terminal-binding protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 2Homo sapiens (human)
viral genome replicationC-terminal-binding protein 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 2Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
temperature homeostasisAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
DNA alkylation repairAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of lipid storageAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
snRNA processingAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of multicellular organism growthAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
RNA repairAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of respiratory system processAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
adipose tissue developmentAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
mRNA destabilizationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of white fat cell proliferationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of brown fat cell differentiationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate secondary active transmembrane transporter activityMonocarboxylate transporter 2Homo sapiens (human)
protein bindingMonocarboxylate transporter 2Homo sapiens (human)
lactate transmembrane transporter activityMonocarboxylate transporter 2Homo sapiens (human)
symporter activityMonocarboxylate transporter 2Homo sapiens (human)
identical protein bindingMonocarboxylate transporter 2Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
transcription corepressor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 2Homo sapiens (human)
protein bindingC-terminal-binding protein 2Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 2Homo sapiens (human)
protein kinase bindingC-terminal-binding protein 2Homo sapiens (human)
protein-containing complex bindingC-terminal-binding protein 2Homo sapiens (human)
NAD bindingC-terminal-binding protein 2Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 2Homo sapiens (human)
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
ferrous iron bindingAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
transferase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
oxidative RNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
broad specificity oxidative DNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
mRNA N6-methyladenosine dioxygenase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
tRNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nucleoplasmMonocarboxylate transporter 2Homo sapiens (human)
cytosolMonocarboxylate transporter 2Homo sapiens (human)
plasma membraneMonocarboxylate transporter 2Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 2Homo sapiens (human)
Schaffer collateral - CA1 synapseMonocarboxylate transporter 2Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseMonocarboxylate transporter 2Homo sapiens (human)
parallel fiber to Purkinje cell synapseMonocarboxylate transporter 2Homo sapiens (human)
postsynaptic density membraneMonocarboxylate transporter 2Homo sapiens (human)
glutamatergic synapseMonocarboxylate transporter 2Homo sapiens (human)
plasma membraneMonocarboxylate transporter 2Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusC-terminal-binding protein 2Homo sapiens (human)
synapseC-terminal-binding protein 2Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 2Homo sapiens (human)
nucleusC-terminal-binding protein 2Homo sapiens (human)
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
nucleusAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
nucleoplasmAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
cytoplasmAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
cytosolAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
plasma membraneAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
nuclear speckAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID1543452Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Inhibition of a viral prolyl hydroxylase.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID734755Inhibition of human hexahistidine-tagged full-length FTO expressed in Escherichia coli BL21 (DE3) using 3-methylthymidine as substrate assessed as inhibition of 3-methylthymidine conversion to thymidine after 1 hr by liquid chromatographic analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Structural basis for inhibition of the fat mass and obesity associated protein (FTO).
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681145TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Genomics, Jan, Volume: 79, Issue:1
The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681605TP_TRANSPORTER: change in intracellular pH(pHi)value in Xenopus laevis oocytes1998The Biochemical journal, Jul-01, Volume: 333 ( Pt 1)Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH.
AID679678TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter.
AID681570TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells2002American journal of physiology. Renal physiology, Jun, Volume: 282, Issue:6
Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT.
AID679950TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter.
AID1298930Inhibition of recombinant His6-tagged CtBP2 (31 to 384 residues) (unknown origin) dehydrogenase activity expressed in Escherichia coli BL21-Codonplus (DE3)-RIL cells using MTOB as substrate after 15 mins by NADH consumption assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID321445Inhibition of Escherichia coli DHDPS2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID679842TP_TRANSPORTER: inhibition of lactate uptake (Lactate:0.1mM, Pyruvate:1mM, preincubation with aminoxyacetate) in Xenopus laevis oocytes1997The Journal of biological chemistry, Nov-28, Volume: 272, Issue:48
Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012The Journal of biological chemistry, Oct-19, Volume: 287, Issue:43
Crystal structure of reaction intermediates in pyruvate class II aldolase: substrate cleavage, enolate stabilization, and substrate specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7,921)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902205 (27.84)18.7374
1990's1291 (16.30)18.2507
2000's1723 (21.75)29.6817
2010's2088 (26.36)24.3611
2020's614 (7.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.69 (24.57)
Research Supply Index9.05 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index152.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (82.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials169 (2.03%)5.53%
Reviews327 (3.94%)6.00%
Case Studies133 (1.60%)4.05%
Observational16 (0.19%)0.25%
Other7,665 (92.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]